ReviewTheScientificWorldJournal2012
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.
Review in TheScientificWorldJournal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 84 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 6 syntheses or guidelines pooled it, 194 citations in OpenAlex.
- Laser therapy for retinopathy in sickle cell disease.The Cochrane database of systematic reviews · 2022Pooled it
- Interventions for treating intrahepatic cholestasis in people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Interventions for treating intrahepatic cholestasis in people with sickle cell disease.The Cochrane database of systematic reviews · 2017Pooled it
- Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.The Cochrane database of systematic reviews · 2015Pooled it
- Laser therapy for retinopathy in sickle cell disease.The Cochrane database of systematic reviews · 2015Pooled it
- A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.Expert review of hematology · 2015Pooled it
- Sensory and Thermal Quantitative Testing in Children With Sickle Cell Disease.Journal of pediatric hematology/oncology · 2015Trial
- The Unfinished Story of Sickle Cell Nephropathy: A Narrative Review of Knowledge Gaps and Research Imperatives.Journal of clinical medicine · 2026Review
- Preliminary Benefits of In-Home Virtual Reality for Chronic Pain in Sickle Cell Disease: Pilot Randomized Trial.Biomedicines · 2026Article
- Septic nonunion of the distal tibia in a sickle cell disease patient: a case report.International journal of surgery case reports · 2026Article
- End-of-Life Care in Sickle Cell Disease and Transfusion-Dependent β-Thalassemia: Clinical, Psychosocial, and Ethical Considerations.Mediterranean journal of hematology and infectious diseases · 2026Review
- Immunopathogenesis of Sickle Cell Disease: Mechanisms of Immune Dysregulation and Clinical Consequences, a Narrative Review.Journal of blood medicine · 2026Review
- Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Knowledge and Experience of In-Home Virtual Reality for Chronic Pain in Sickle Cell Disease.The journal of pain · 2024Article
- Advancing life: innovative approaches to enhance survival in sickle cell anemia patients.Annals of medicine and surgery (2012) · 2024Review
- Effects of GBT1118, a voxelotor analog, on bone disease in sickle cell disease mice.Scientific reports · 2024Article
- Inpatient Management of Pain Episodes in Children with Sickle Cell Disease: A Review.Children (Basel, Switzerland) · 2024Review
- Opioid Control for Patients With Sickle Cell Anemia in Emergency Departments in the Western Region of Saudi Arabia.Cureus · 2024Article
- Review
- Management of diabetes mellitus patients with sickle cell anemia: Challenges and therapeutic approaches.Medicine · 2024Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
The sickle hemoglobin is an abnormal hemoglobin due to point mutation (GAG → GTG) in exon 1 of the β globin gene resulting in the substitution of glutamic acid by valine at position 6 of the β globin polypeptide chain. Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that constitute the various complications of sickle cell disease in general and sickle cell anemia in particular. The disease itself is chronic in nature but many of its complications are acute such as the recurrent acute painful crises (its hallmark), acute chest syndrome, and priapism. These complications vary considerably among patients, in the same patient with time, among countries and with age and sex. To date, there is no well-established consensus among providers on the management of the complications of sickle cell disease due in part to lack of evidence and in part to differences in the experience of providers. It is the aim of this paper to review available current approaches to manage the major complications of sickle cell disease. We hope that this will establish another preliminary forum among providers that may eventually lead the way to better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.